Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

6.690 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,878
Open 6.690
Bid (Size) 6.760 (1)
Ask (Size) 6.850 (2)
Prev. Close 6.690
Today's Range 6.690 - 6.690
52wk Range 4.970 - 15.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-32.22%
-32.22%
1 Month
-22.21%
-22.21%
3 Month
-29.65%
-29.65%
6 Month
-46.18%
-46.18%
1 Year
-23.10%
-23.10%

More News

Read More
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
From Recursion Pharmaceuticals
Via GlobeNewswire
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
From FN Media Group LLC
Via GlobeNewswire
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
Via The Motley Fool
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024
Via InvestorPlace
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Is Recursion Pharmaceuticals a Millionaire-Maker?
Via The Motley Fool
99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
Via Talk Markets
Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
25 Best Artificial Intelligence Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Millionaire-Maker Artificial Intelligence (AI) Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
Is Recursion Pharmaceuticals Stock a Buy?
Via The Motley Fool
1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.